JOAN TOBAR: Open Payments
NPI 1366057671 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$549 in 15 payments from 11 companies in 2025. Trend: 2023 $451 · 2024 $395 · 2025 $549
Food & beverage: $549
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. | 1 | $148 |
| Novartis Pharmaceuticals Corporation | 2 | $118 |
| Calliditas Therapeutics US Inc. | 3 | $83 |
| SCPHARMACEUTICALS INC. | 2 | $38 |
| GENZYME CORPORATION | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk Inc | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
Products named: SYMPLICITY G3, Vanrafia, TARPEYO, FUROSCIX, FABRAZYME, KEVEYIS, Kerendia, Ozempic.
Industry payments across MI — which companies pay providers there.
